Insurers and state Medicaid agencies have been eager to strike a deal with pharmaceutical companies to secure discounts on pricey hepatitis C drugs.
Both insurers and state Medicaid agencies are working to secure discounts on pricey hepatitis C drugs.
Insurers and states alike have been eager to strike a deal with the pharmaceutical companies, especially considering
the backlash Gilead's Sovaldi received last year after the company placed a $100,000 per person price tag on the drug. Harvoni is Gilead's follow-up to Sovaldi.
Missouri signed a deal with AbbVie this week to make Viekira Park the preferred drug covered by the state's Medicaid program, noted the Wall Street Journal
. The drug will replace Sovaldi. AbbVie will "provide a rebate to states participating in the consortium."
Read more: http://bit.ly/15UL9hm
Source: Fierce Health Payer